131 related articles for article (PubMed ID: 7380205)
1. Spironolactone and enzyme induction in patients with alcoholic cirrhosis.
Miguet JP; Vuitton D; Thebault-Lucas A; Joanne C; Dhumeaux D
Gastroenterology; 1980 May; 78(5 Pt 1):996-1000. PubMed ID: 7380205
[TBL] [Abstract][Full Text] [Related]
2. Decreased hepatic microsomal reserve in patients with cirrhosis. Studies using aminopyrine as model drug.
Piken E; Hepner GW
J Lab Clin Med; 1979 Dec; 94(6):947-54. PubMed ID: 501215
[TBL] [Abstract][Full Text] [Related]
3. Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child-Pugh C liver cirrhosis: randomized prospective trial.
Degoricija V; Zjacic-Rotkvic V; Marout J; Sefer S; Troskot B
Croat Med J; 2003 Apr; 44(2):178-86. PubMed ID: 12698509
[TBL] [Abstract][Full Text] [Related]
4. Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
Wensing G; Hoffmann K; Heidemann HT
Z Gastroenterol; 1993 Jan; 31(1):15-9. PubMed ID: 8447150
[TBL] [Abstract][Full Text] [Related]
5. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites.
Okumura H; Aramaki T; Katsuta Y; Satomura K; Akaike M; Sekiyama T; Terada H; Ohsuga M; Komeichi H; Tsutsui H
Am J Gastroenterol; 1991 Jan; 86(1):46-52. PubMed ID: 1986554
[TBL] [Abstract][Full Text] [Related]
6. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
[TBL] [Abstract][Full Text] [Related]
7. Attenuation by spironolactone of the magnesiuric effect of acute frusemide administration in patients with liver cirrhosis and ascites.
Stergiou GS; Mayopoulou-Symvoulidou D; Mountokalakis TD
Miner Electrolyte Metab; 1993; 19(2):86-90. PubMed ID: 8377729
[TBL] [Abstract][Full Text] [Related]
8. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
Debruyne D; Gram LF; Grollier G; Camsonne R; Agron L; Dao MT; Lacotte J; Bigot MC; Moulin M
Int J Clin Pharmacol Res; 1989; 9(5):319-25. PubMed ID: 2625371
[TBL] [Abstract][Full Text] [Related]
9. [The metabolic clearance rate of antipyrine: a good index for the assessment of the hepatic drug-oxidizing function in cirrhotic patients (author's transl)].
Miguet JP; Allemand H; Joanne C; Dhumeaux D
Nouv Presse Med; 1978 Dec; 7(46):4209-11. PubMed ID: 745958
[No Abstract] [Full Text] [Related]
10. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
[TBL] [Abstract][Full Text] [Related]
11. [Furosemide-amiloride combination in the treatment of ascitic-edema in patients with hepatic cirrhosis].
Uribe M; Rojas S; Casián C; Sierra JG; Moreno J; Lewis H; Guevara L
Rev Gastroenterol Mex; 1980; 45(2):63-8. PubMed ID: 7403764
[TBL] [Abstract][Full Text] [Related]
12. Hepatic drug metabolizing capacity of patients of cirrhosis before and after clinico-biochemical recovery.
Chauhan CK; Nanivadekar SA; Billimoria FR
Indian J Physiol Pharmacol; 1989; 33(1):63-6. PubMed ID: 2737749
[TBL] [Abstract][Full Text] [Related]
13. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Katsaraki A; Tsianos EV
Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218
[TBL] [Abstract][Full Text] [Related]
14. Increased values of antipyrine clearance in type IV hyperlipoproteinemia.
Bedeleanu D; Trif I; Lötsch JC; Cucuianu MP
Med Interne; 1986; 24(3):183-90. PubMed ID: 3775212
[TBL] [Abstract][Full Text] [Related]
15. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.
Branch RA; Shand DG; Wilkinson GR; Nies AS
J Clin Invest; 1974 Apr; 53(4):1101-7. PubMed ID: 4205524
[TBL] [Abstract][Full Text] [Related]
16. Colchicine clearance is impaired in alcoholic cirrhosis.
Leighton JA; Bay MK; Maldonado AL; Schenker S; Speeg KV
Hepatology; 1991 Dec; 14(6):1013-5. PubMed ID: 1959847
[TBL] [Abstract][Full Text] [Related]
17. Effect of phenobarbital and spironolactone treatment on the oxidative metabolism of antipyrine by rat liver microsomes.
Szakács T; Veres Z; Vereczkey L
Pol J Pharmacol; 2001; 53(1):11-9. PubMed ID: 11785906
[TBL] [Abstract][Full Text] [Related]
18. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
Ohnhaus EE; Münch U; Meier J
Schweiz Med Wochenschr; 1976 Dec; 106(49):1748-50. PubMed ID: 1013699
[TBL] [Abstract][Full Text] [Related]
19. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
[TBL] [Abstract][Full Text] [Related]
20. Spironolactone interference with digoxin radioimmunoassay in cirrhotic patients.
DiPiro JT; Cote JR; DiPiro CR; Bustrack JA
Am J Hosp Pharm; 1980 Nov; 37(11):1518-21. PubMed ID: 7211855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
